title: Comparison of Mean Overall Survival (OS) and Radiographic Progression Free Survival (RPFS) Based on Matching Adjusted Indirect Comparison of Abiraterone Acetate and Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Chemotherapy Naïve Patients.
authors.affiliation: Janssen, High Wycombe, UK.
authors.forename: L
authors.initials: L
authors.lastname: Dearden
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: I
authors.initials: I
authors.lastname: Majer
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: B
authors.initials: B
authors.lastname: Heeg
authors.affiliation: Janssen-Cilag AB, Sollentuna, Sweden.
authors.forename: J
authors.initials: J
authors.lastname: Liwing
authors.affiliation: Janssen-Cilag AB, Sollentuna, Sweden.
authors.forename: K
authors.initials: K
authors.lastname: Sandstrom
authors.affiliation: Janssen Research & Development, Beerse, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Diels